|Professor Mark Cooper|
Professor Mark Cooper is the Head of the Department of Diabetes and was recently made an Officer of the Order of Australia for his service to biomedical research in the field of Diabetes.
Professor Cooper will be presenting on "the changing face in managing diabetes and its complications". Abstract below:
After more than 50 years of managing diabetes primarily with insulin, sulphonylureas and metformin as well as diet and exercise, over the last decade the treatment options have been greatly expanded.
New drugs that surprisingly do not target the pathways that are considered critical in the pathogenesis of type 2 diabetes, i.e. insulin resistance and beta cell dysfunction, have now entered the armamentarium for the treatment of diabetes. We have 3 major classes of drugs that not only lower glucose levels but also appear to have better side effect profiles and in certain circumstances may confer specific actions to reduce diabetic micro- and macrovascular complications. These agents include DPP-IV inhibitors, GLP-1 analogues and SGLT2 inhibitors. In addition, there has been rapid progress in our understanding of the underlying pathophysiology of diabetic complications, which it is hoped will lead to new targets and ultimately new therapies to reduce the major burden of both type 1 and type 2 diabetes their complications.
We look forward to welcoming Professor Cooper for the Symposium!
Translational Research Symposium
- Date: Monday 31 July, 2017
- Time: 8:30 for 9:00am start - 7:00pm close
- RSVP here
If you are a graduate student or early career researcher, you may be interested in the Young Investigator poster competition. See here for more details and to RSVP.